{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:02:30Z","timestamp":1781244150874,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.lungcan.2015.06.018","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T06:59:58Z","timestamp":1435042798000},"page":"223-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Second line therapy in malignant pleural mesothelioma: A systematic review"],"prefix":"10.1016","volume":"89","clinical-trial-number":[{"clinical-trial-number":"nct01098266","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01358084","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01843374","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01870609","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02399371","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Wieneke A.","family":"Buikhuisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta I.","family":"Hiddinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"van Meerbeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2015.06.018_bib0310","first-page":"311","article-title":"The Helsinki Consensus report on diagnosis and attribution","volume":"23","author":"Anonymous","year":"1997","journal-title":"Scand. J. Work Environ. Health"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0315","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br. J. Ind. Med."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0320","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0325","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","article-title":"The worldwide pandemic of asbestos-related diseases","volume":"34","author":"Stayner","year":"2013","journal-title":"Annu. Rev. Public Health"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0330","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0335","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0340","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0345","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2011.07.011","article-title":"Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma","volume":"75","author":"Woods","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0350","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1183\/09031936.00153611","article-title":"Population-based survival for malignant mesothelioma after introduction of novel chemotherapy","volume":"40","author":"Damhuis","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0355","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0360","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","article-title":"The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent","volume":"13","author":"Gehan","year":"1961","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0365","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0370","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0375","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/JTO.0b013e31817c73ec","article-title":"Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program","volume":"3","author":"Taylor","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0380","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S1556-0864(15)30351-8","article-title":"Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program","volume":"1","author":"Janne","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0385","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1556-0864(15)30366-X","article-title":"The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline","volume":"1","author":"Ellis","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0390","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JTO.0b013e31802f3813","article-title":"Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment","volume":"2","author":"Sorensen","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0395","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0400","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"issue":"Suppl. 8","key":"10.1016\/j.lungcan.2015.06.018_bib0405","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(02)80018-1","article-title":"Phase II trial of ZD0473 as second-line therapy in mesothelioma","volume":"38","author":"Giaccone","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0410","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/COC.0b013e3181cae90e","article-title":"Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study","volume":"34","author":"Tourkantonis","year":"2011","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0415","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.lungcan.2004.11.015","article-title":"Raltitrexed\u2013oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients","volume":"48","author":"Porta","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0420","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1200\/JCO.2003.05.123","article-title":"Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study","volume":"21","author":"Fizazi","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0425","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1158\/1078-0432.CCR-08-1579","article-title":"Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma","volume":"15","author":"Vandermeers","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0430","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.00037310","article-title":"Valproate\u2013doxorubicin: promising therapy for progressing mesothelioma. A phase II study","volume":"37","author":"Scherpereel","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0435","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0440","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","article-title":"Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus","volume":"140","author":"Li","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0445","series-title":"ASCO Annual Meeting","article-title":"SWOG 0722: a phase II study of mTOR inhibitor everolimus (RAD 001) in malignant pleural mesothelioma (MPM)","author":"Garland","year":"2012"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0450","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3020","article-title":"A first in human phase 1 study to evaluate GDC-0980, an oral P13K\/mTOR inhibitor, administered QD in patients with advanced solid tumors","volume":"29","author":"Wagner","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0455","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0460","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0465","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","article-title":"BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization","volume":"68","author":"Ventii","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0470","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0475","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0480","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J. Pathol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0485","first-page":"2063","article-title":"Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma","volume":"18","author":"Linder","year":"1998","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0490","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0495","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D","article-title":"Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma","volume":"182","author":"Kumar-Singh","year":"1997","journal-title":"J. Pathol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0500","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0505","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0510","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0515","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0520","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0525","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0530","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0535","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0540","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2009.27.3649","article-title":"Phase II study of asparagine\u2013glycine\u2013arginine\u2013human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma","volume":"28","author":"Gregorc","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0545","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","article-title":"A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma","volume":"81","author":"Nowak","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0550","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2005.04.010","article-title":"Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial","volume":"50","author":"Mathy","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0555","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/JTO.0b013e318248242c","article-title":"Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report","volume":"7","author":"Dudek","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0560","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0565","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0570","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0575","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0580","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.7531","article-title":"A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients","volume":"32","author":"Calabro","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0585","series-title":"AACR Annual Meeting","article-title":"Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-001","author":"Alley","year":"2015"},{"key":"10.1016\/j.lungcan.2015.06.018_bib0590","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0595","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: a new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0600","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"Chowdhury","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2015.06.018_bib0605","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2015.06.018_bib0610","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","article-title":"Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma","volume":"7","author":"Fennell","year":"2012","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215300015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215300015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T15:47:10Z","timestamp":1566920830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500215300015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0169500215300015"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.06.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second line therapy in malignant pleural mesothelioma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}